Online inquiry

IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14104MR)

This product GTTS-WQ14104MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14104MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4780MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ2983MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ7219MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ6859MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ2991MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ14635MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ6393MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ7297MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW